AmerisourceBergen Promotes Barbara A. Brungess to Vice President, Corporate and Investor Relations

Published on Tuesday, 03 August 2010 08:12 Written by TradersHuddle Staff

VALLEY FORGE, Pa.-( Business Wire )-

AmerisourceBergen Corporation (NYSE: ABC) today announced the promotion of Barbara A. Brungess to Vice President, Corporate & Investor Relations, effective immediately. She is responsible for investor relations and external communications for the Company, and reports directly to Michael M. DiCandilo, Executive Vice President and Chief Financial Officer.

Brungess succeeds Michael N. Kilpatric, currently Vice President Corporate & Investor Relations, who is retiring, effective December 31, 2010, and will provide transition support until then.

“Barbara brings a deep and broad knowledge of the Company to her new role,” said R. David Yost, AmerisourceBergen President and Chief Executive Officer. “She joined AmerisourceBergen 10 years ago in the Investor Relations office, and has steadily grown her responsibilities and leadership within that department.”

“I also want to thank Mike for his leadership and dedication to AmerisourceBergen during the 10 years he has been with the Company,” Yost continued. “His integrity, knowledge and communication skills have served AmerisourceBergen and our shareholders extremely well.”

Brungess holds a Master of Science in Financial Services from St. Joseph’s University in Philadelphia; a Master of Arts in Political Science from Pennsylvania State University; and a Bachelor of Arts in Politics from Ursinus College in Collegeville, PA.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $75 billion in annualized revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. AmerisourceBergen is ranked #24 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

FORWARD-LOOKING STATEMENTS

Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management’s current expectations and are subject to uncertainty and change in circumstances. Among the factors that could cause actual results to differ materially from those projected, anticipated or implied are the following: changes in pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships; changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or insolvencies; changes in pharmaceutical manufacturers’ pricing and distribution policies or practices; adverse resolution of any contract or other dispute with customers or suppliers; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; qui tam litigation for alleged violations of laws and regulations governing the marketing, sale and purchase of pharmaceutical products or any related litigation, including shareholder derivative lawsuits; changes in U.S. legislation or regulatory action affecting pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare; changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceutical products we distribute, including certain anemia products; price inflation in branded pharmaceuticals and price deflation in generics; greater or less than anticipated benefit from launches of the generic versions of previously patented pharmaceutical products; significant breakdown or interruption of our information technology systems; our inability to implement an enterprise resource planning (ERP) system to handle business and financial processes within AmerisourceBergen Drug Corporation’s operations and our corporate functions without operating problems and/or cost overruns; success of integration, restructuring or systems initiatives; interest rate and foreign currency exchange rate fluctuations; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States, including potential changes in Canadian provincial legislation affecting pharmaceutical product pricing or service fees or regulatory action by provincial authorities in Canada to lower pharmaceutical product pricing or service fees; the impact of divestitures or the acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; our inability to successfully complete any other transaction that we may wish to pursue from time to time; changes in tax legislation or adverse resolution of challenges to our tax positions; increased costs of maintaining, or reductions in our ability to maintain, adequate liquidity and financing sources; volatility and deterioration of the capital and credit markets; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting our business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for this Fiscal Year Ended September 30, 2009 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.

AmerisourceBergen CorporationMichael N. This e-mail address is being protected from spambots. You need JavaScript enabled to view it.